Education
About Us
Working with TipRanks
Follow Us
Indivior PLC (INDV)
NASDAQ:INDV
INDV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.33 - $25.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.20M
Market Cap
$2.87B
Enterprise Value$1.71B
Total Cash (Recent Filing)$510.00M
Total Debt (Recent Filing)$366.00M
Price to Earnings (P/E)32.3
Beta0.57
Next Earnings
Oct 23, 2025EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding124,769,820
10 Day Avg. Volume2,041,521
30 Day Avg. Volume2,203,038
Financial Highlights & Ratios
PEG Ratio22.18
Price to Book (P/B)-4.71
Price to Sales (P/S)1.38
P/FCF Ratio234.39
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue1.46
Enterprise Value/Gross Profit1.74
Enterprise Value/Ebitda6.28
Forecast
1Y Price Target
$207.86Price Target Upside808.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Financial StrengthIndivior is well-positioned to fund any legal obligations, reinvest in its lead assets, and pursue share repurchases or accretive transactions with $538M in cash and investments.
Market StabilityThe outlook looks better since Sublocade vs Brixadi dynamic looks mostly stabilized, and CJS headwinds are well understood, indicating potential for Sublocade to return to growth.
Product DifferentiationRecent label updates to Sublocade differentiate the product in its ability to start patients earlier as it is the only monthly LAI to initiate therapy on Day 1, without a 7-day oral induction.
Bears Say
Competitive PressureSublocade was ultimately $100M below initial guidance from competitor Brixadi share gains and also CJS funding disruption.
Operational EfficiencyAnalyst thinks INDV is overspending on G&A and the operational structure can be much more efficient.
Indivior News
INDV FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest stock price was $7.33 and its highest was $25.10 in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is $2.87B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Oct 23, 2025 which is in 33 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Jul 31, 2025. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.25.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 0.39.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 124,769,820 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of $0.51 in its last earnings report, beating expectations of $0.26. Following the earnings report the stock price went up 16.092%.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in INDV
Indivior Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$207.86 (808.08% Upside)
$207.86 (808.08% Upside)
Blogger Sentiment
Bullish
INDV Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 75.5K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.41%
Trailing 12-Months
Company Description
Indivior PLC
Indivior PLC is a global pharmaceutical company focused on developing medicines to treat addiction and its related disorders. The company's primary sector is pharmaceuticals, specializing in addiction treatment. Indivior's core products include medications for opioid dependence, such as the Suboxone Film, which combines buprenorphine and naloxone, and Sublocade, an extended-release injection for opioid use disorder.
INDV Company Deck
INDV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Indivior's record-breaking performance with SUBLOCADE, upwardly revised financial guidance, and strategic initiatives to streamline operations and improve execution. However, challenges such as pricing pressure on SUBOXONE Film and opportunities for improvement in U.S. commercial execution were acknowledged. Despite these challenges, the overall sentiment leans towards the positive due to the significant achievements and strategic roadmap.View all INDV earnings summariesINDV Stock 12 Month Forecast
Average Price Target
$207.86
▲(808.08% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
4.95% Insiders
3.90% Mutual Funds
49.83% Other Institutional Investors
36.38% Public Companies and
Individual Investors